Overview
Following the success of the Future of Evidence and Digital Health Workshops, we now transfer these topics to a new conference in the EMEA region – the DIA Future of Evidence and Smart Health Conference. Combining regulatory and science perspectives in a unique forum, this conference discusses opportunities and implementation strategies within the EU data and digital landscape – to support regulators, industry, and patients. Explore latest developments in data usage and data storage, innovative approaches to integrated evidence, and how artificial intelligence and machine learning can transform drug development. The conference will gear you up to drive actionable outcomes and contribute to advancing the EU regulatory space.
The conference program follows two main tracks:
Real-world Evidence (RWE)
RWE data is a valuable source to help optimize clinical trial design and support decision-making for regulators, physicians, and other healthcare providers. We explore how to define the quality of different types of RWE sources and how to best approach a unified framework for clinical data collection. Understand how various stakeholders are leveraging RWE to advance healthcare knowledge and decision-making processes, which are increasingly in the hands of artificial intelligence tools.
Digital Health
With a deep dive into the fast-evolving digital healthcare ecosystem, you will be introduced to novel wearables and data collection methods. You further get insights into new formats of digital intervention in health. In interdisciplinary sessions, we approach hot topics like the Dynamic Dossier in the cloud, rapid reviews, and digital therapeutics which could help fulfill unmet medical needs caused by limitations in traditional therapies.
Featured topics
- Application of AI & ML in Drug Development and Approval
- Regulatory Landscape RWE and Digital Health - Challenges and Opportunities
- EU Data Landscape
- Real-World Evidence Data Sources and Data Quality
- Innovative approaches to integrated evidence
- Innovative Design Using Real-World Evidence and Novel End Points
- Blockchain in Drug Development
- RCT Duplicate
- Cloud based systems for data storage
Featured
Who should attend?
- Professionals involved in:
- Clinical operations and clinical development
- Data Management, Privacy and Science
- Data Science, data and analytics
- R&D big data
- Real World Evidence
- Regulatory Innovation and Regulatory Science
- Digital Health and Solutions
- Patient Advocacy
- Innovation
- Policy
- Epidemiology
- Artificial Intelligence and Machine Learning
- Market Access & Reimbursement
Program Committee
-
Thomas Brookland, MSc • EU Data and AI Policy Lead
F. Hoffmann-La Roche Ltd., Switzerland -
Adrian Cassidy, PhD, MSc • Global Head of RWE and Data Science
Novartis, Switzerland -
Michael Lees, MA • Chief Operating Officer and Head of Market Access Strategy
PHMR Ltd, United Kingdom -
Solène Thieffry, MSc • Global RWE Policy Lead
UCB, Belgium -
Emma Du Four, MBA • Head of International Regulatory Policy
AbbVie, United Kingdom -
Cécile Mathilde Ollivier, MS • Managing Director Europe
Critical Path Institute, Netherlands
